These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26828124)

  • 1. Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.
    Uzun A; Yalcindag FN; Demirel S; Batýoðlu F; Ozmert E
    Ocul Immunol Inflamm; 2017 Apr; 25(2):229-232. PubMed ID: 26828124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study.
    Demirel S; Bilici S; Batıoğlu F; Özmert E
    Ophthalmic Res; 2016; 56(1):35-40. PubMed ID: 27027523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.
    Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M
    Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Choi KE; Hwang SY; Kim SW; Huh K
    BMC Ophthalmol; 2016 Mar; 16():25. PubMed ID: 26951107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients.
    Nomura Y; Takahashi H; Tan X; Fujino Y; Kawashima H; Yanagi Y
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):53-7. PubMed ID: 25863675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kim JH; Shin JP; Kim IT; Park DH
    Retina; 2018 Mar; 38(3):523-530. PubMed ID: 28151839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept.
    Shiraya T; Kure K; Araki F; Kato S; Kaiya T
    Jpn J Ophthalmol; 2020 May; 64(3):250-256. PubMed ID: 32108920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients.
    Mottet B; Aptel F; Geiser MH; Hera R; Zhou T; Almanjoumi A; Vinh V; Chiquet C
    Acta Ophthalmol; 2018 Nov; 96(7):e783-e788. PubMed ID: 30203609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.
    Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ
    Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration.
    Lee KH; Chin HS; Kim NR; Moon YS
    Korean J Ophthalmol; 2015 Dec; 29(6):396-403. PubMed ID: 26635456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.